Answers are grounded in this paper and cite their sources.
Background : Immune checkpoint inhibitors (ICI) are antitumor agents employed in the treatment of hepatocellular carcinoma (HCC), which enhance T-cell function by targeting immune escape pathways.HCC is classified into viral and non-viral types based on its etiology, with the viral form often linked to an immunosuppressive microenvironment due to T-cell tolerance.However, existing research on how viral etiology influences ICI therapy outcomes is limited.This study evaluated the efficacy and safety of ICI in viral versus non-viral HCC in a Korean population.
No takes yet. Share an insight, caveat, or question.
Lee et al. (2024) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: